Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.

Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N

Open source

DOI: 10.1158/1078-0432.ccr-23-1429
Published: 2023 Nov 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-23-1429,
  title = {Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.},
  author = {Senapati J and Fiskus WC and Daver N and Wilson NR and Ravandi F and Garcia-Manero G and Kadia T and DiNardo CD and Jabbour E and Burger J and Short NJ and Alvarado Y and Jain N and Masarova L and Issa GC and Qiao W and Khoury JD and Pierce S and Miller D and Sasaki K and Konopleva M and Bhalla KN and Borthakur G and Pemmaraju N},
  year = {2023},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-23-1429},
  url = {https://doi.org/10.1158/1078-0432.ccr-23-1429}
}

RIS

TY  - JOUR
TI  - Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
AU  - Senapati J
AU  - Fiskus WC
AU  - Daver N
AU  - Wilson NR
AU  - Ravandi F
AU  - Garcia-Manero G
AU  - Kadia T
AU  - DiNardo CD
AU  - Jabbour E
AU  - Burger J
AU  - Short NJ
AU  - Alvarado Y
AU  - Jain N
AU  - Masarova L
AU  - Issa GC
AU  - Qiao W
AU  - Khoury JD
AU  - Pierce S
AU  - Miller D
AU  - Sasaki K
AU  - Konopleva M
AU  - Bhalla KN
AU  - Borthakur G
AU  - Pemmaraju N
PY  - 2023
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-23-1429
UR  - https://doi.org/10.1158/1078-0432.ccr-23-1429
ER  -

APA

J, S., WC, F., N, D., NR, W., F, R., G, G., T, K., CD, D., E, J., J, B., NJ, S., Y, A., N, J., L, M., GC, I., W, Q., JD, K., S, P., D, M., K, S., M, K., KN, B., G, B., & N, P. (2023). Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-1429

Source records

pubmed · retrieved 2026-09-26T08:41:29.493Z